Evidence map›Paper›PMID 42509412›Full record

ReviewAnnals of surgical oncology2026

ASO Practice Guidelines Series: Resectable Colorectal Cancer.

Ramy Behman, George J Chang

Abstract readReview
In one paragraph

Review in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ramy BehmanUniversity of Texas MD Anderson Cancer Center - Colon and Rectal Surgery, Houston, TX, USA.
George J ChangUniversity of Texas MD Anderson Cancer Center - Colon and Rectal Surgery, Houston, TX, USA. GChang@mdanderson.org.ORCID http://orcid.org/0000-0002-9758-5361

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer remains a leading cause of cancer morbidity and mortality worldwide. Despite biologic similarities, colon and rectal cancers require distinct management strategies. Rapid advances molecular characterization (including mismatch repair status) as well as paradigm shifts in neoadjuvant therapy and organ-preservation strategies have expanded the range of treatment approaches while increasing the need for clear, guideline-anchored decision-making. This Practice Guidelines Series article summarizes contemporary guidance from major international guidelines (National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and Japanese Society for Cancer of the Colon and Rectum (JSCCR)), highlighting areas of recent evolution and ongoing debate.

Indexed as

Colorectal NeoplasmsPractice Guidelines as TopicColorectal Surgical ProceduresHumansNeoadjuvant TherapyColon cancerMismatch repair deficiencyPractice guidelinesRectal cancerTotal neoadjuvant therapy

Identifiers

PMID42509412
PMCPMC13675274

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.